The full name of DIC is diffuse intravascular coagulation, and the anemia produced by DIC is classified as microangiopathic hemolytic anemia. DIC is induced by a variety of underlying diseases, such as systemic infections such as bacterial and viral infections, or multiple traumatic injuries, extensive burns, and traumatic injuries, as well as by malignant tumors such as leukemia and myeloproliferative disorders.DIC is not a stand-alone disease, but rather a clinicopathological syndrome that produces coagulation dysfunction in the course of the progression of many diseases. As a result of diffuse activation of the coagulation mechanism within the blood, it not only triggers extensive fibrin deposition in small vessels, leading to tissue and organ damage, but also causes systemic bleeding tendencies due to depletion of coagulation factors. In the early stage of the coagulation reaction, fibrin filaments form a fine mesh within the microvessels, and when circulating red blood cells flow through the fine mesh holes, they adhere, stay or hang on to the fibrin filaments, and hypoxia and acidosis occur, which reduces the deformation ability of red blood cells. At the same time, under the constant impact of blood flow, hemolysis occurs when red blood cells rupture, so it can lead to anemia in patients, and at the same time, hemorrhage, shock, and impaired function of various organs can occur. As the triggering factors of DIC and the severity of clinical manifestations vary, the individual determines the therapeutic decision of the disease.The key to the treatment of DIC is to strengthen the treatment of the underlying disease, eliminate the triggering factors of DIC, and increase the survival rate of the patients.